Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms

Y. Chalandon, DJ. Eikema, I. Moiseev, F. Ciceri, L. Koster, J. Vydra, J. Passweg, M. Rovira, T. Ozcelik, T. Gedde-Dahl, N. Kröger, V. Potter, I. Yakoub-Agha, A. Rambaldi, M. Itälä-Remes, A. Tanase, F. Onida, C. Gurnari, C. Scheid, J....

. 2024 ; 8 (18) : 4792-4802. [pub] 20240924

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018868

It has been reported in prospective randomized trials that antithymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis has benefits in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with unrelated donors (UDs). However, the optimal GVHD prophylaxis strategy has been challenged recently by the increasing use of posttransplant cyclophosphamide (PTCY). We report from the European Society for Blood and Marrow Transplantation registry the outcomes of 960 patients with myelodysplastic neoplasms who underwent allo-HSCT from UD with PTCY or ATG as GVHD prophylaxis. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The disease characteristics were similar in both groups. Day 28 neutrophil engraftment was significantly better with ATG (93% vs 85%). Over a median follow-up of 4.4 years, the 5-year OS was 58% with PTCY, and 49% in the ATG group. The 5-year PFS was higher for PTCY at 53% vs 44% for ATG. Grade 2 to 4 acute GVHD incidence was lower when PTCY was used (23%), whereas there was no difference in the incidence of chronic GVHD at 5 years. Multivariable analyses confirmed better OS and PFS with PTCY with a hazard ratio (HR) for ATG of 1.32 (1-1.74) and a better PFS for PTCY with a HR for ATG of 1.33. This study suggests that GVHD prophylaxis using PTCY instead of ATG in this setting remains a valid option. Further prospective randomized studies would be essential to confirm these results.

Bone Marrow Transplantation Unit Haematology Department Institute of Haematology and Oncology IDIBAPS Hospital Clinic University of Barcelona Barcelona Spain

CHU de Lille Univ Lille INSERM U1286 INFINITE 59000 Lille France

Demiroglu Bilim University Istanbul Florence Nightingale Hospital Istanbul Turkey

Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy

Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy

EBMT Leiden Statistical Unit Leiden The Netherlands

EBMT Leiden Study Unit Leiden The Netherlands

Fundeni Clinical Institute Bucharest Romania

Hematology and BMT Unit ASST Fatebenefratelli Sacco University of Milan Milan Italy

Hôpital Saint Louis APHP Université de Paris Cité Paris France

Hôpitaux Universitaires de Genève and Faculty of Medicine University of Geneva Geneva Switzerland

Institute of Hematology and Blood Transfusion Prague Czech Republic

King's College Hospital London United Kingdom

Oslo University Hospital Rikshospitalet Oslo Oslo Norway

Ospedale San Raffaele s r l Milan Italy

RM Gorbacheva Research Institute Pavlov University St Petersburg Russia

Turku University Hospital Turku Finland

University Clinical Centre Medical University of Warsaw Warsaw Poland

University College London Hospitals NHS Foundation Trust London United Kingdom

University Hospital Basel Basel Switzerland

University Hospital Eppendorf Hamburg Germany

University of Cologne Cologne Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018868
003      
CZ-PrNML
005      
20241024111124.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2024013468 $2 doi
035    __
$a (PubMed)39008719
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chalandon, Yves $u Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland $1 https://orcid.org/0000000193418104
245    10
$a Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms / $c Y. Chalandon, DJ. Eikema, I. Moiseev, F. Ciceri, L. Koster, J. Vydra, J. Passweg, M. Rovira, T. Ozcelik, T. Gedde-Dahl, N. Kröger, V. Potter, I. Yakoub-Agha, A. Rambaldi, M. Itälä-Remes, A. Tanase, F. Onida, C. Gurnari, C. Scheid, J. Drozd-Sokolowska, K. Raj, DP. McLornan, M. Robin
520    9_
$a It has been reported in prospective randomized trials that antithymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis has benefits in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with unrelated donors (UDs). However, the optimal GVHD prophylaxis strategy has been challenged recently by the increasing use of posttransplant cyclophosphamide (PTCY). We report from the European Society for Blood and Marrow Transplantation registry the outcomes of 960 patients with myelodysplastic neoplasms who underwent allo-HSCT from UD with PTCY or ATG as GVHD prophylaxis. The primary outcomes were overall survival (OS) and progression-free survival (PFS). The disease characteristics were similar in both groups. Day 28 neutrophil engraftment was significantly better with ATG (93% vs 85%). Over a median follow-up of 4.4 years, the 5-year OS was 58% with PTCY, and 49% in the ATG group. The 5-year PFS was higher for PTCY at 53% vs 44% for ATG. Grade 2 to 4 acute GVHD incidence was lower when PTCY was used (23%), whereas there was no difference in the incidence of chronic GVHD at 5 years. Multivariable analyses confirmed better OS and PFS with PTCY with a hazard ratio (HR) for ATG of 1.32 (1-1.74) and a better PFS for PTCY with a HR for ATG of 1.33. This study suggests that GVHD prophylaxis using PTCY instead of ATG in this setting remains a valid option. Further prospective randomized studies would be essential to confirm these results.
650    _2
$a lidé $7 D006801
650    12
$a cyklofosfamid $x terapeutické užití $7 D003520
650    12
$a antilymfocytární sérum $x terapeutické užití $7 D000961
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a transplantace hematopoetických kmenových buněk $x metody $x škodlivé účinky $7 D018380
650    12
$a nemoc štěpu proti hostiteli $x prevence a kontrola $x etiologie $7 D006086
650    _2
$a dospělí $7 D000328
650    12
$a nepříbuzný dárce $7 D061349
650    12
$a myelodysplastické syndromy $x terapie $x mortalita $7 D009190
650    _2
$a senioři $7 D000368
650    _2
$a mladý dospělý $7 D055815
650    _2
$a homologní transplantace $7 D014184
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a mladiství $7 D000293
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Eikema, Diderik-Jan $u EBMT Leiden Statistical Unit, Leiden, The Netherlands
700    1_
$a Moiseev, Ivan $u RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia $1 https://orcid.org/0000000243320114
700    1_
$a Ciceri, Fabio $u Ospedale San Raffaele s.r.l., Milan, Italy
700    1_
$a Koster, Linda $u EBMT Leiden Study Unit, Leiden, The Netherlands
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
700    1_
$a Passweg, Jakob $u University Hospital Basel, Basel, Switzerland
700    1_
$a Rovira, Montserrat $u Bone Marrow Transplantation Unit, Haematology Department, Institute of Haematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
700    1_
$a Ozcelik, Tulay $u Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Istanbul, Turkey
700    1_
$a Gedde-Dahl, Tobias $u Oslo University Hospital, Rikshospitalet Oslo, Oslo, Norway $1 https://orcid.org/0000000230375378
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000151039966
700    1_
$a Potter, Victoria $u King's College Hospital, London, United Kingdom
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ Lille, INSERM U1286, INFINITE 59000, Lille, France $1 https://orcid.org/0000000345248782
700    1_
$a Rambaldi, Alessandro $u Department of Oncology and Hematology, University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy $1 https://orcid.org/0000000237397502 $7 xx0317376
700    1_
$a Itälä-Remes, Maija $u Turku University Hospital, Turku, Finland $1 https://orcid.org/0000000158441632
700    1_
$a Tanase, Alina $u Fundeni Clinical Institute, Bucharest, Romania
700    1_
$a Onida, Francesco $u Hematology and BMT Unit, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy
700    1_
$a Gurnari, Carmelo $u Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy $1 https://orcid.org/0000000168295544
700    1_
$a Scheid, Christof $u University of Cologne, Cologne, Germany $1 https://orcid.org/000900076539226X
700    1_
$a Drozd-Sokolowska, Joanna $u University Clinical Centre, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Raj, Kavita $u University College London Hospitals NHS Foundation Trust, London, United Kingdom $1 https://orcid.org/000000028258354X
700    1_
$a McLornan, Donal P $u University College London Hospitals NHS Foundation Trust, London, United Kingdom
700    1_
$a Robin, Marie $u Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France $1 https://orcid.org/0000000313889876
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 18 (2024), s. 4792-4802
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39008719 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111117 $b ABA008
999    __
$a ok $b bmc $g 2201624 $s 1230841
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 18 $d 4792-4802 $e 20240924 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace